Leading the Way in Life Science Technologies

GEN Exclusives

More »

Metabolic Diseases - Related Content

  • Page 1 of 1 (5 items) 1 
  • GEN Podcasts
  • PROTEIN IMPORTANT IN DIABETES FOUND TO PLAY ROLE IN OTHER DISEASES
    Struan Grant, Ph.D., is Associate Director of the Center for Applied Genomics at the Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics, Department of Pediatrics, University of Pennsylvania School of Medicine
  • NOVEL CANCER THERAPY MAY ARISE FROM DWARF POPULATION STUDY
    - Interview with Valter D. Longo, Ph.D., Associate Professor, Gerontology and Alzheimer's Research, Biological Sciences, College of Letters Arts & Sciences, Leonard Davis School of Gerontology, University of Southern California
  • ANTIBODY FIGHTS FAT
    - Interview with Kim Janda, Ph.D., Ely R. Callaway, Jr. Professor of Chemistry, Member of The Skaggs Institute for Chemical Biology, and Director of the Worm Institute of Research and Medicine, Scripps Research Institute
  • BREATH TEST FOR DISEASE DIAGNOSIS
    - Interview with Masood Yousef, Ph.D., senior research assistant in the Welsh Centre for Printing and Coating, Swansea University School of Engineering
  • LINKING CHANGES IN GENE NETWORKS TO DISEASE
    - Interview with Eric Schadt, Ph.D., Executive Scientific Director of Research Genetics for Rosetta Inpharmatics, Inc., a wholly-owned subsidiary of Merck & Co.
  • Page 1 of 1 (5 items) 1 

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »